Market Intelligence, Clinical Progress, and High-Purity Reagents for Synthetic Lethality, DNA Repair, and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BARD1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BARD1 Full-Length / RING Domain / BRCT Domain Recombinant Protein; also mutant panel available. High purity (>95%), Endotoxin <1EU/ug, Sequence Verified. Theoretical MW confirmed by LC-MS. | View BARD1 Products |
| Gene Delivery | BARD1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. CMV promoter, Puromycin selection. HEK293 Expressed. | View BARD1 Products |
| Benchmark Ab | Anti-BARD1 (Clone 7B8 Reference Sequence). Recombinant positive control for Western/IP. Sequence Verified, Endotoxin Controlled. | View BARD1 Products |
| Validator | BARD1 siRNA Set (3 target-specific + 1 control). For knockdown verification in HR repair assays. | View BARD1 Products |
| Cancer Mutant Panel | BARD1 C557R / R658C / Gln564Ter Mutant Proteins (plus rs1048108, rs753377280, rs16852741 variants). Cancer susceptibility variants for resistance screening. | View BARD1 Products |
| Related Target A | BRCA1. Direct heterodimeric partner; essential for E3 ubiquitin ligase activity and HR repair. | View BRCA1 Products |
| Related Target B | PARP1. Synthetic lethality axis; core target for combination strategy validation in BARD1-deficient tumors. | View PARP1 Products |
| Related Target C | RAD51. Downstream HR mediator; pathway integrity and resistance mechanism studies. | View RAD51 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| BRCA1-BARD1 Heterodimer Disruption (PPI inhibition) | Sequence-verified RING domains for both partners. High-purity proteins (>95%) for SPR/ITC. Native folding confirmed by CD spectroscopy. Human/Mouse/Cyno orthologs available. |
| Cancer Mutant Variant Screening | C557R, R658C, truncating mutants available. Wild-type vs mutant comparative assays supported. Clinical variant panel includes rs1048108, rs753377280, rs16852741. |
| Isoform Specificity (WT vs Splice Variants) | Strictly sequence-verified isoform panels (Theoretical MW confirmed). |
| Ubiquitination Activity Validation | Auto-ubiquitination competent. E2 enzyme (UBE2D1/2/3) compatibility. |
| Subcellular Localization Studies | Lentivirus particles with nuclear localization sequence preservation. Stable integration for DNA damage foci assays. |
| Lack of Reliable Assay Controls | Validated siRNA and CRISPR-compatible ORF clones included. Clinical-grade benchmark antibodies (Biosimilars). |
Live BARD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The landscape for BARD1-targeted intervention is transitioning from biomarker discovery to mechanistic drug discovery. As the central heterodimeric partner of BRCA1, BARD1 represents a critical node in homologous recombination (HR) repair and synthetic lethality networks. Major R&D efforts are shifting from traditional cytotoxics toward precision modalities that disrupt the BARD1-BRCA1 RING-RING interface or exploit BARD1-deficient contexts. With first-generation PARP inhibitors reaching maturity, resistance mechanisms are emerging, driving the next wave of research that targets BARD1-specific vulnerabilities—including oncogenic splice variants (e.g., BARD1β) and protein degraders (PROTACs) designed to disrupt the heterodimer in specific cancer subsets such as ovarian carcinoma, neuroblastoma, and platinum-resistant solid tumors. The integration of BARD1 mutations into HRD testing panels (e.g., by AstraZeneca, GSK) further underscores its biomarker value, while direct BARD1 inhibitors are anticipated to enter clinical trials by 2025–2027.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitor | Academic Consortia, Emerging Biotech | Breast, Ovarian, Pancreatic, Neuroblastoma | TR-FRET / AlphaScreen with purified BARD1-BRCA1 RING domains; selectivity against mutant vs WT. |
| PROTAC / Molecular Glue | Frontier Biotech, Arvinas, C4 Therapeutics | Advanced Solid Tumors, Resistance Reversal | Ternary complex formation assays requiring full-length BARD1; ubiquitination competence assays. |
| Synthetic Lethality Combinations | AstraZeneca, Pfizer, GSK | BRCA1/2 Wild-type tumors with BARD1 loss; Platinum-resistant Ovarian | HR repair deficiency assays using Lentivirus for stable reporter cell lines; synthetic lethality reporter assays with mutant vs WT proteins. |
| PARP Inhibitor Resistance Modifiers | Daiichi Sankyo, GSK | Platinum-resistant Ovarian Cancer | DNA damage foci quantification; validated siRNA controls for specificity. |
| siRNA / Antisense | Gene Silencing Specialists | BARD1-overexpressing Cancers | Knockdown rescue assays using Lentivirus ORF and validated siRNA; off-target control panels. |